ARS Pharmaceuticals (SPRY) Change in Accured Expenses (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Change in Accured Expenses data on file, last reported at $10.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 147.48% year-over-year to $10.3 million; the trailing twelve-month figure through Mar 2026 stood at $25.0 million (up 30.1% YoY), and the FY2025 full-year result was $18.9 million, up 15.04% from the prior year.
• Change in Accured Expenses grew to $10.3 million in Q1 2026, from -$9.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $12.8 million in Q2 2025 to a low of -$11.4 million in Q4 2022.
• A 5-year average of $1.9 million and a median of $1.3 million in 2024 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses jumped 1268.75% in 2024 and plunged 218.27% in 2025, its largest moves.
• Tracing SPRY's Change in Accured Expenses over 5 years: stood at -$11.4 million in 2022, then grew by 22.25% to -$8.9 million in 2023, then soared by 186.3% to $7.7 million in 2024, then sank by 218.27% to -$9.1 million in 2025, then jumped by 213.8% to $10.3 million in 2026.
• Business Quant data shows SPRY's Change in Accured Expenses at $10.3 million in Q1 2026, -$9.1 million in Q4 2025, and $11.0 million in Q3 2025.